Mariner Wealth Advisors LLC Grows Stake in iShares NASDAQ Biotechnology Index (IBB)

Mariner Wealth Advisors LLC lifted its position in iShares NASDAQ Biotechnology Index (NASDAQ:IBB) by 549.7% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 19,854 shares of the financial services provider’s stock after purchasing an additional 16,798 shares during the quarter. Mariner Wealth Advisors LLC’s holdings in iShares NASDAQ Biotechnology Index were worth $2,120,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently made changes to their positions in IBB. CHURCHILL MANAGEMENT Corp grew its holdings in shares of iShares NASDAQ Biotechnology Index by 223.2% in the fourth quarter. CHURCHILL MANAGEMENT Corp now owns 1,801,330 shares of the financial services provider’s stock valued at $192,328,000 after purchasing an additional 1,244,066 shares during the period. Clal Insurance Enterprises Holdings Ltd grew its holdings in shares of iShares NASDAQ Biotechnology Index by 175.5% in the third quarter. Clal Insurance Enterprises Holdings Ltd now owns 635,875 shares of the financial services provider’s stock valued at $212,132,000 after purchasing an additional 405,091 shares during the period. Main Management LLC grew its holdings in shares of iShares NASDAQ Biotechnology Index by 190.5% in the fourth quarter. Main Management LLC now owns 461,801 shares of the financial services provider’s stock valued at $49,306,000 after purchasing an additional 302,839 shares during the period. Lockheed Martin Investment Management Co. grew its holdings in shares of iShares NASDAQ Biotechnology Index by 200.0% in the fourth quarter. Lockheed Martin Investment Management Co. now owns 329,400 shares of the financial services provider’s stock valued at $35,170,000 after purchasing an additional 219,600 shares during the period. Finally, Harel Insurance Investments & Financial Services Ltd. grew its holdings in shares of iShares NASDAQ Biotechnology Index by 199.9% in the fourth quarter. Harel Insurance Investments & Financial Services Ltd. now owns 313,485 shares of the financial services provider’s stock valued at $33,470,000 after purchasing an additional 208,963 shares during the period. 38.31% of the stock is owned by hedge funds and other institutional investors.

Shares of iShares NASDAQ Biotechnology Index (NASDAQ:IBB) opened at $109.25 on Wednesday. iShares NASDAQ Biotechnology Index has a 1-year low of $94.20 and a 1-year high of $119.30.

TRADEMARK VIOLATION NOTICE: “Mariner Wealth Advisors LLC Grows Stake in iShares NASDAQ Biotechnology Index (IBB)” was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this news story on another publication, it was stolen and reposted in violation of United States and international trademark and copyright law. The original version of this news story can be viewed at https://www.dispatchtribunal.com/2018/02/21/mariner-wealth-advisors-llc-grows-stake-in-ishares-nasdaq-biotechnology-index-ibb.html.

About iShares NASDAQ Biotechnology Index

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.

Want to see what other hedge funds are holding IBB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iShares NASDAQ Biotechnology Index (NASDAQ:IBB).

Institutional Ownership by Quarter for iShares NASDAQ Biotechnology Index (NASDAQ:IBB)

Receive News & Ratings for iShares NASDAQ Biotechnology Index Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares NASDAQ Biotechnology Index and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply